Vernalis Selects IDBS’ E-WorkBook for Chemistry as Part of Company-Wide ELN Deployment
News May 21, 2009
IDBS has announced that Vernalis has purchased E-WorkBook Suite for chemistry (ChemBook) as its corporate chemistry data management solution.
Vernalis sought an application that would provide its scientists with chemistry technologies, as well as offering complete access to all its chemistry and IP related data. ChemBook - a chemistry-specific extension to IDBS’ enterprise class E-WorkBook Suite - incorporates IDBS’ advanced chemistry technologies by offering a chemically ‘aware’ spreadsheet for data analysis and statistical trending.
The decision to select the E-WorkBook Suite was based on the product’s ability to adapt to specific workflows, achieved through configuration – as opposed to customization - of the solution.
Jo Lerpiniere, Senior Informatics Scientist for Vernalis commented: “We were unanimous in choosing the E-WorkBook Suite as our data management solution. IDBS impressed us over its competitors as the E-WorkBook Suite could be configured to meet our needs.”
The E-WorkBook Suite manages multiple process workflows within and between groups. Flexible and searchable reports are generated across all data stored within the notebook, including file and spectral annotations.
Jo Lerpiniere continued: “IDBS were willing and helpful in demonstrating solutions to streamline our workflow and our aim is to replace all paper based lab notebooks with their ELN. The E-WorkBook Suite is a practical and adaptable choice of ELN that easily integrates with our workflow.”
Neil Kipling, founder and CEO of IDBS commented: “We are delighted to be working with Vernalis and providing E-WorkBook Suite to meet their current and future research data management requirements. Vernalis’ decision to invest in, and deploy, our solution in their chemistry area is a clear recognition that ChemBook is an influential product in this market. IDBS’ ongoing investment in chemistry and data management technologies will continue to keep our products at the forefront of research informatics.”
Organizations looking to benefit from the artificial intelligence (AI) revolution should be cautious about putting all their eggs in one basket, a study published in Nature Machine Intelligence has found. Researchers found that contrary to conventional wisdom, there can be no exact method for deciding whether a given problem may be successfully solved by machine learning tools.READ MORE
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE